Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
[Featured Stock] Green Life Sciences, hits the limit up after signing a 10 billion won AI semiconductor material supply contract
Green Life Sciences surged after news that it has signed an AI semiconductor materials supply contract worth 10.05 billion Korean won.
According to information from the Korea Exchange, Green Life Sciences briefly touched the daily limit-up price during intraday trading, closing at 3,645 Korean won. The sharp jump in the stock price is seen as being driven by investor sentiment boosted by the announcement of a large-scale supply contract targeting its affiliate company, Green Chemical.
The announcement shows the contract value is 10.05 billion Korean won, equivalent to 24.91% of its standalone benchmark sales of 40.3 billion Korean won in 2025. The contract runs from May 18 to December 31, 2026, with the supply area being domestic. The company said the quantity and amount will be determined based on the receipt of customer orders.
The market is paying close attention to the contract, viewing it as a sizable single-supply agreement. The contract is about one quarter of its sales, and as it supplies AI semiconductor materials, the related growth expectations are reflected in the impact on the stock price.
Previously, Green Life Sciences was a company based on precision chemical technology, developing and producing pharmaceutical ingredient materials, electronic materials, and crop protection agents. Founded in 2005, it listed on the KOSDAQ market in 2009. It was the first in South Korea to develop the piperacillin-class antibiotic intermediate EDP-CL and became the first domestic synthesis plant to receive U.S. FDA approval.
The contract is also interpreted as a case of achieving supply results in the electronic materials sector by leveraging its existing strengths in precision chemical technology.